Other Events ·
Pharming Group N.V. announced the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients…
PHARPharming Group N.V.
Pharming Group N.V. announced the commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with activated PI3K delta syndrome (APDS) aged 4 years and older, following its inclusion on the Japan National Health Insurance drug price list. This marks the first commercial availability of Joenja for children aged 4 to 11 worldwide. OrphanPacific, Inc. serves as the Marketing Authorization holder responsible for supply and distribution in Japan under an agreement with Pharming. The launch follows approval by Japan’s Ministry of Health, Labour and Welfare (MHLW) in March 2026. Leverne Marsh, Chief Commercial Officer, described this as a significant milestone in global expansion addressing unmet needs in rare disease communities. Pharming Group N.V. is a global biopharmaceutical company dedicated to developing and commercializing innovative medicines for rare, debilitating, and life-threatening diseases.